SCHEMBL5358558

SCHEMBL5358558

[O]C(=O)c1cccc2ncc3ccccc3c12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
GPR3 P46089 1/20 0.50
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
PIM1 P11309 1/20 0.39
MGAM O43451 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MMP3 P08254 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CNR1 P21554 1/20 0.37
PTPN1 P18031 1/20 0.37
CDC25B P30305 1/20 0.37
PLK1 P53350 1/20 0.37
KDR P35968 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28032410 0.89 KDM4E (0.52) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL5358564 0.87 NR4A1 (0.53) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL8230482 0.86 PIM1 (0.50) KDM4EGPR3PIM1ALDH1A1MEN1
SCHEMBL27546968 0.83 KDM4E (0.46) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL18663455 0.83 KDM4E (0.46) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL27656141 0.81 KDM4E (0.44) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL27656146 0.81 KDM4E (0.44) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL30075099 0.81 KDM4E (0.50) KDM4EGPR3NR4A1NR4A2NR4A3
SCHEMBL3862098 0.80 LIG1 (0.46) KDM4EGPR3MGAMALDH1A1HPGD
SCHEMBL29598792 0.76 KDM4E (0.57) KDM4EGPR3ALDH1A1HDAC8HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 KDM4E 855/4885GPR3 372/4885NR4A1 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.